Get the Stockscreener App
22.34
17.58%
3.34
After Hours:
22.33
-0.01
-0.04%
Apellis Pharmaceuticals Inc stock is traded at $22.34, with a volume of 7.00M.
It is up +17.58% in the last 24 hours and up +29.06% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$19.00
Open:
$20.65
24h Volume:
7.00M
Relative Volume:
2.76
Market Cap:
$2.81B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-11.00
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+11.20%
1M Performance:
+29.06%
6M Performance:
-22.99%
1Y Performance:
-43.59%
1-Day Range:
$20.45
$23.56
1-Week Range:
$18.48
$23.56
52-Week Range:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.34 | 2.39B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - Insider Monkey
Apellis Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
10 Stocks Crushing With Whopping Double-Digit Gains - Insider Monkey
Apellis Pharmaceuticals' Q2 2025: Unraveling Contradictions in Sales Dynamics, Market Position, and Competitive Landscape - AInvest
Apellis Says Investors’ ‘Reframed’ Appeal Still Scientific Spat - Bloomberg Law News
Apellis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Apellis Q2 2025 slides: EMPAVELI approval offsets revenue decline By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Apellis (APLS) Reports Lower Q2 Revenue and Celebrates FDA Approval - GuruFocus
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - The Manila Times
Apellis Pharma earnings beat by $0.15, revenue fell short of estimates - Investing.com Canada
Apellis Q2 2025 revenue $178mln, cash $370mln, FDA approves EMPAVELI. - AInvest
Apellis Scores Major FDA Approval for EMPAVELI, Secures $300M Deal and Reports Strong Q2 Earnings - Stock Titan
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval - BioPharma Dive
Scotiabank raises Apellis Pharmaceuticals stock price target on FDA approval By Investing.com - Investing.com Canada
Scotiabank raises Apellis Pharmaceuticals stock price target on FDA approval - Investing.com
Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN
What To Expect From Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings - Yahoo Finance
Apellis wins US approval for Empaveli in rare kidney diseases - The Pharma Letter
What makes Apellis Pharmaceuticals Inc. stock price move sharplyTrade Ready Stock Watch for Short Term Published - metal.it
AI Tools Suggest Apellis Pharmaceuticals Inc. May Outperform This WeekSecure Capital Picks With Upside Potential Tracked - metal.it
Citigroup Raises Apellis Pharmaceuticals (APLS) Price Target to $46 | APLS Stock News - GuruFocus
Apellis’ Empaveli Expansion Underway In Rare Kidney Disease - insights.citeline.com
Apellis’ Empaveli approved in US for two rare kidney diseases - BioWorld MedTech
Apellis wins FDA label expansion for Empaveli (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals stock price target raised to $21 by Mizuho - Investing.com Canada
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio - inkl
How Apellis Pharmaceuticals Inc. stock performs during market volatilitySmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $29 to $60 - 富途牛牛
Cantor Fitzgerald reiterates Overweight rating on Apellis stock after FDA approval - Investing.com Canada
Apellis shares jump 12% following FDA approval of first-ever C3G treatment - MSN
Apellis stock soars after FDA approves first C3G treatment By Investing.com - Investing.com India
Apellis stock soars after FDA approves first C3G treatment - Investing.com
Apellis Pharmaceuticals' FDA Approval of EMPAVELI for C3G and IC-MPGN: A Game-Changer in Rare Kidney Disease Therapeutics - AInvest
Apellis (APLS) Gains Boost with Increased Price Target and FDA Approval - GuruFocus
Apellis secures FDA approval for Empaveli to treat rare kidney diseases - World Pharmaceutical Frontiers
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment? - simplywall.st
Fierce Biotech Layoff Tracker 2025: Merck launches cost-cutting efforts; Moderna cuts 10% of all roles - Fierce Biotech
Apellis APLS 2025Q2 Earnings Preview Upside Ahead on EMPAVELI Trial Initiations - AInvest
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - Santé log
Trendlines Suggest Apellis Pharmaceuticals Inc. May Bottom Out SoonRisk Controlled Picks With Real Returns Outlined - metal.it
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the - GlobeNewswire
FDA Approves First Treatment for Rare Kidney Disease C3G, Shows 68% Efficacy | APLS Stock News - Stock Titan
How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Invest confidently with proven investment plans - jammulinksnews.com
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals - Stocktwits
Is it the right time to buy Apellis Pharmaceuticals Inc. stockMaximize gains with strategic stock entries - jammulinksnews.com
What is Apellis Pharmaceuticals Inc. company’s growth strategyUnlock exclusive stock market forecasts - jammulinksnews.com
How does Apellis Pharmaceuticals Inc. compare to its industry peersAchieve exceptional returns with expert guidance - jammulinksnews.com
What are Apellis Pharmaceuticals Inc. company’s key revenue driversLow Risk Report For Consistent Profits - jammulinksnews.com
RSI Suggests Rebound May Be Near in Apellis Pharmaceuticals Inc.Stock Portfolio Allocation Guidance for Volatile Markets - metal.it
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):